DK0941344T3 - Humaniserede anti-CD11a-antistoffer - Google Patents
Humaniserede anti-CD11a-antistofferInfo
- Publication number
- DK0941344T3 DK0941344T3 DK97912841T DK97912841T DK0941344T3 DK 0941344 T3 DK0941344 T3 DK 0941344T3 DK 97912841 T DK97912841 T DK 97912841T DK 97912841 T DK97912841 T DK 97912841T DK 0941344 T3 DK0941344 T3 DK 0941344T3
- Authority
- DK
- Denmark
- Prior art keywords
- humanized anti
- cd11a antibodies
- cd11a
- antibodies
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75720596A | 1996-11-27 | 1996-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0941344T3 true DK0941344T3 (da) | 2004-09-27 |
Family
ID=25046834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97912841T DK0941344T3 (da) | 1996-11-27 | 1997-10-20 | Humaniserede anti-CD11a-antistoffer |
| DK04004941.3T DK1516629T3 (da) | 1996-11-27 | 1997-10-20 | Humaniseret anti-CD-11a antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04004941.3T DK1516629T3 (da) | 1996-11-27 | 1997-10-20 | Humaniseret anti-CD-11a antibodies |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1516629B1 (enExample) |
| JP (2) | JP3778945B2 (enExample) |
| KR (1) | KR100532178B1 (enExample) |
| AR (1) | AR008919A1 (enExample) |
| AT (1) | ATE267257T1 (enExample) |
| AU (1) | AU731817C (enExample) |
| CA (1) | CA2272842C (enExample) |
| DE (3) | DE122004000047I1 (enExample) |
| DK (2) | DK0941344T3 (enExample) |
| ES (1) | ES2221045T3 (enExample) |
| FR (1) | FR04C0028I2 (enExample) |
| IL (3) | IL130143A0 (enExample) |
| LU (1) | LU91122I2 (enExample) |
| NL (1) | NL300163I2 (enExample) |
| PT (1) | PT941344E (enExample) |
| WO (1) | WO1998023761A1 (enExample) |
| ZA (1) | ZA979599B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| SI1135498T1 (sl) | 1998-11-18 | 2008-06-30 | Genentech Inc | Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi |
| ES2301254T3 (es) | 1998-11-18 | 2008-06-16 | Genentech, Inc. | Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales. |
| EP1854480A3 (en) * | 1999-03-19 | 2009-04-01 | Genentech, Inc. | Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist |
| US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
| ES2311483T3 (es) * | 1999-12-14 | 2009-02-16 | Genentech, Inc. | Anatagonista del tnf-alfa y antagonista del lfa-1 para el tratamiento de la artritis reumatoide. |
| US7560275B2 (en) | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
| US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
| WO2001051084A1 (en) * | 2000-01-14 | 2001-07-19 | Genentech, Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
| AU2001287000A1 (en) * | 2000-09-01 | 2002-03-13 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| US20020151050A1 (en) | 2000-10-30 | 2002-10-17 | Vacanti Charles A. | Isolation of spore-like cells from tissues exposed to extreme conditions |
| DK1472275T3 (da) | 2002-02-05 | 2009-04-14 | Genentech Inc | Proteinoprensning |
| EP1501369B1 (en) | 2002-04-26 | 2015-06-24 | Genentech, Inc. | Non-affinity purification of proteins |
| JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック， インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| KR100872210B1 (ko) * | 2003-04-23 | 2008-12-05 | 메다렉스, 인코포레이티드 | 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체 |
| SI1648940T1 (sl) | 2003-07-28 | 2016-08-31 | Genentech, Inc. | Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A |
| CA2554965C (en) * | 2004-02-19 | 2015-08-11 | The Cbr Institute For Biomedical Research, Inc. | Antibodies specific for activated conformation of lfa-1 |
| EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
| BRPI0511305A (pt) * | 2004-06-09 | 2007-12-04 | Genentech Inc | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
| NZ577933A (en) | 2007-01-22 | 2011-12-22 | Genentech Inc | Polyelectrolyte precipitation and purification of antibodies |
| KR101851580B1 (ko) | 2007-07-09 | 2018-04-25 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
| EP3605088A1 (en) | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
| EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
| FI3604324T3 (fi) | 2008-08-14 | 2024-05-16 | Genentech Inc | Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa |
| EP2684570A1 (en) | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
| SG171764A1 (en) | 2008-12-16 | 2011-07-28 | Millipore Corp | Purification of proteins |
| DK2370561T3 (da) | 2008-12-16 | 2019-10-21 | Emd Millipore Corp | Omrøringstankreaktor og fremgangsmåde |
| ES2547712T3 (es) | 2009-02-27 | 2015-10-08 | Genentech, Inc. | Métodos y composiciones para el marcado de proteínas |
| MY186219A (en) | 2009-08-11 | 2021-06-30 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
| RU2571929C2 (ru) | 2009-09-01 | 2015-12-27 | Дженентек, Инк. | Улучшенная очистка белка посредством модифицированного элюирования белка а |
| KR20120089339A (ko) | 2009-11-12 | 2012-08-09 | 브이비아이 테크놀로지스, 엘엘씨 | 포자를 닮은 세포들의 계군 및 그 용도 |
| US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| EP3513810A1 (en) | 2010-03-22 | 2019-07-24 | F. Hoffmann-La Roche AG | Compositions and methods useful for stabilizing protein- containing formulations |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| SG184541A1 (en) | 2010-05-17 | 2012-11-29 | Emd Millipore Corp | Stimulus responsive polymers for the purification of biomolecules |
| PL2576580T3 (pl) | 2010-05-28 | 2017-03-31 | F.Hoffmann-La Roche Ag | Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej |
| AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
| EP2603525A1 (en) | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Antibodies to il-1beta and il-18, for treatment of disease |
| WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
| SG11201403437TA (en) | 2011-12-22 | 2014-07-30 | Genentech Inc | Ion exchange membrane chromatography |
| KR102096678B1 (ko) | 2012-03-27 | 2020-04-02 | 제넨테크, 인크. | 재조합 단백질을 위한 개선된 수확 작업 |
| MX389346B (es) | 2012-05-18 | 2025-03-20 | Genentech Inc | Formulaciones de anticuerpos monoclonales de alta concentración. |
| EP2934602B1 (en) | 2012-12-19 | 2019-02-27 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
| SI3019240T1 (sl) * | 2013-07-09 | 2024-07-31 | Annexon, Inc. | Protitelesa proti komplementnemu faktorju C1q in njihova uporaba |
| KR20250007687A (ko) | 2013-07-16 | 2025-01-14 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
| BR112017000142B1 (pt) | 2014-07-09 | 2021-08-17 | Genentech, Inc | Métodos para melhorar a recuperação por descongelamento de bancos de células e para congelamento de células cho para armazenamento, grupo de células cho para o congelamento de células de mamíferos, e banco de células |
| US10316081B2 (en) | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| KR20220104289A (ko) | 2015-09-25 | 2022-07-26 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
| IL296130A (en) | 2015-11-24 | 2022-11-01 | Annexon Inc | Anti-complement factor c1q fab fragments and their uses |
| KR20190012145A (ko) | 2016-03-29 | 2019-02-08 | 젤터, 인코포레이티드 | 주변세포질 부피 대 세포질 부피의 비가 0.5:1 내지 10:1인 그람-음성 박테리아에서의 단백질의 발현 |
| CN110049778A (zh) | 2016-12-22 | 2019-07-23 | 豪夫迈·罗氏有限公司 | 减少冻干多肽重构时间的方法和制剂 |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| JP7419273B2 (ja) | 2018-07-03 | 2024-01-22 | ブリストル－マイヤーズ スクイブ カンパニー | 組換えタンパク質を製造する方法 |
| CN113166695A (zh) | 2018-10-10 | 2021-07-23 | 勃林格殷格翰国际公司 | 用于高密度生物反应器培养中的膜气体转移的方法 |
| EP3946457A1 (en) | 2019-04-01 | 2022-02-09 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
| JP7777451B2 (ja) | 2019-04-12 | 2025-11-28 | ジェルター， インコーポレイテッド | 組換えエラスチンおよびその産生 |
| WO2021021973A1 (en) | 2019-08-01 | 2021-02-04 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
| CN116194570A (zh) | 2020-09-22 | 2023-05-30 | 百时美施贵宝公司 | 用于产生治疗性蛋白的方法 |
| WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
| US20240390869A1 (en) | 2021-09-21 | 2024-11-28 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
| WO2023114763A1 (en) | 2021-12-13 | 2023-06-22 | Annexon, Inc. | Anti-complement factor c1q antibodies with single binding arms and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
-
1997
- 1997-10-20 DE DE200412000047 patent/DE122004000047I1/de active Pending
- 1997-10-20 DE DE1997629209 patent/DE122004000047I2/de active Active
- 1997-10-20 CA CA2272842A patent/CA2272842C/en not_active Expired - Lifetime
- 1997-10-20 JP JP52464598A patent/JP3778945B2/ja not_active Expired - Lifetime
- 1997-10-20 AU AU49929/97A patent/AU731817C/en not_active Expired
- 1997-10-20 PT PT97912841T patent/PT941344E/pt unknown
- 1997-10-20 ES ES97912841T patent/ES2221045T3/es not_active Expired - Lifetime
- 1997-10-20 KR KR10-1999-7004671A patent/KR100532178B1/ko not_active Expired - Lifetime
- 1997-10-20 IL IL13014397A patent/IL130143A0/xx active IP Right Grant
- 1997-10-20 DK DK97912841T patent/DK0941344T3/da active
- 1997-10-20 AT AT97912841T patent/ATE267257T1/de active
- 1997-10-20 DE DE69729209T patent/DE69729209T2/de not_active Expired - Lifetime
- 1997-10-20 WO PCT/US1997/019041 patent/WO1998023761A1/en not_active Ceased
- 1997-10-20 EP EP04004941A patent/EP1516629B1/en not_active Expired - Lifetime
- 1997-10-20 DK DK04004941.3T patent/DK1516629T3/da active
- 1997-10-20 EP EP97912841A patent/EP0941344B1/en not_active Expired - Lifetime
- 1997-10-27 ZA ZA979599A patent/ZA979599B/xx unknown
- 1997-11-04 AR ARP970105146A patent/AR008919A1/es active IP Right Grant
-
1999
- 1999-05-26 IL IL130143A patent/IL130143A/en not_active IP Right Cessation
-
2004
- 2004-11-10 LU LU91122C patent/LU91122I2/fr unknown
- 2004-11-12 NL NL300163C patent/NL300163I2/nl unknown
- 2004-12-10 FR FR04C0028C patent/FR04C0028I2/fr active Active
-
2005
- 2005-08-02 JP JP2005224609A patent/JP4309383B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-11 IL IL175583A patent/IL175583A0/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0941344T3 (da) | Humaniserede anti-CD11a-antistoffer | |
| CY2005008I1 (el) | Αντισωματα αντι - vegf | |
| NO955167D0 (no) | Monoklonalt anti- | |
| DK0837927T3 (da) | Anti-CD80-antistoffer | |
| NO985464D0 (no) | Konsentrert antistoffpreparat | |
| DE69920897D1 (de) | Monoklonale antikörper mit verringerter immunisierungsfähigkeit | |
| DK145493D0 (da) | Antistof | |
| DE69622451D1 (de) | Funktelefon | |
| FI964845A7 (fi) | CD44v6:n vastaiset monoklonaaliset vasta-aineet | |
| FI951568A7 (fi) | Immobilisoitu beta-mannaasi | |
| DE69625078D1 (de) | Analysator | |
| DE69609663D1 (de) | Automatische Analysevorrichtung | |
| DE69738312D1 (de) | Hepatitis b monoklonale antikörper | |
| NO981454L (no) | Anti-FAS-antistoffer | |
| DE69624334D1 (de) | Fixiervorrichtung | |
| KR970025982U (ko) | 콘센트 | |
| BR9609863A (pt) | Fecho | |
| DE69618534D1 (de) | Fixiervorrichtung | |
| KR960036248U (ko) | 도마 | |
| BR9709080A (pt) | Anticorpo monoclonal anti-MP52 humano | |
| KR970003345U (ko) | 콘센트 | |
| KR960035664U (ko) | 콘센트 | |
| KR970018128U (ko) | 토건용 축조부재 | |
| KR970020763U (ko) | 도마 | |
| ITMI950511A0 (it) | Fotodensitometro parallelo perfezionato |